Antineoplastic Agents: Cytotoxic Agents: Alkylating Agents
IENDO1 “Endoxan injection” 200 mg/vial
OENDO1 “Endoxan tablet” 50 mg/tab
適應症：淋巴性白血病、散發性腫瘤、慢性淋巴性白血病、骨髓性淋巴病、淋巴肉芽腫及各種網狀組織細胞增多症、防止腫瘤復發。
Usual dose:
Leukemias, Breast cancer: (single agent) 40-50 mg/kg IV in divided doses over 2-5 days or 10-15 mg/kg IV q7-10d or 3-5 mg/kg IV twice/wk; oral cyclophosphamide is usually administered at dosages in the range of 1-5 mg/kg/day for both initial and maintenance dosing.
Lupus nephritis: 1 g/m2/mon IV; typically combined with a corticosteroid.
Multiple myeloma (single agent): 40-50 mg/kg IV in divided doses over 2-5 days or 10-15 mg/kg IV q7-10d or 3-5 mg/kg IV twice weekly.
Adverse effect:
Common: alopecia, amenorrhea, leucopenia.
Serious: hemorrhagic cystitis, infections, interstitial pneumonitis, oligospermia/azoospermia, Stevens-Johnson syndrome/toxic epidermal necrolysis.
Related Entries
(Visited 21 times, 1 visits today)